Key facts
- This page summarizes Eric Dobmeier's Form 4 filing for CHINOOK THERAPEUTICS, INC..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Feb 2022, 16:25.
Eric Dobmeier - 31 Jan 2022 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC.
- Reporting relationship
- President, CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 31 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Feb 2022, 16:25:10 UTC
- Prior SEC filing
- 27 Dec 2021
- Next SEC filing
- 14 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kirk Schumacher, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Dobmeier filed Form 4 for CHINOOK THERAPEUTICS, INC. on 02 Feb 2022.
Change
- Previous filing in this sequence was filed on 27 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KDNY
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +300,000
- Change %
- Price
- $0.000000
- Shares after
- 300,000
- Date
- 31 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 300,000
- Exercise price
- $12.90
- Footnotes
- F1
KDNY
transaction
Derivative
Restricted Stock (RSU)(Common Stock)
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 31 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The stock option vests as to 25% of the total shares on January 31, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Footnote F2
Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
Footnote F3
The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.